Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoshihisa Koga is active.

Publication


Featured researches published by Yoshihisa Koga.


Journal of Pharmacology and Experimental Therapeutics | 2012

Pharmacological Characterization of (3S)-3-(Hydroxymethyl)-4-(5-Methylpyridin-2-yl)-N-[6-(2,2,2-Trifluoroethoxy)pyridin-3-yl]-3,4-Dihydro-2H-Benzo[b][1,4]Oxazine-8-Carboxamide (JTS-653), a Novel Transient Receptor Potential Vanilloid 1 Antagonist

Yoshihiro Kitagawa; Atsuko Miyai; Kenji Usui; Yuji Hamada; Katsuya Deai; Masashi Wada; Yoshihisa Koga; Masahiro Sakata; Mikio Hayashi; Makoto Tominaga; Mutsuyoshi Matsushita

Transient receptor potential vanilloid 1 (TRPV1) activation in peripheral sensory nerve is known to be associated with various pain-related diseases, thus TRPV1 has been the focus as a target for drug discovery. In this study, we characterized the pharmacological profiles of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel TRPV1 antagonist. JTS-653 displaced [3H]resiniferatoxin binding to human and rat TRPV1. JTS-653 competitively antagonized the capsaicin-induced activation of human TRPV1 with pA2 values of 10.1. JTS-653 also inhibited proton-induced activation of human and rat TRPV1 with IC50 values of 0.320 and 0.347 nM, respectively. Electrophysiological studies indicated that JTS-653 blocked heat-induced inward currents in rat TRPV1 with IC50 values of 1.4 nM. JTS-653 showed weak or no inhibitory effects on other TRP channels, receptors, and enzymes. JTS-653 significantly prevented capsaicin-induced mechanical hyperalgesia at 1 mg/kg p.o. and attenuated carrageenan-induced mechanical hyperalgesia at 0.3 mg/kg p.o. JTS-653 significantly attenuated carrageenan-induced thermal hyperalgesia at 0.1 mg/kg p.o. and fully reversed at 0.3 mg/kg p.o. without affecting the volume of the carrageenan-treated paw. JTS-653 showed a transient increase of body temperature at 0.3 mg/kg p.o. These results indicated that JTS-653 is a highly potent and selective TRPV1 antagonist in vitro and in vivo and suggested that JTS-653 is one of the most potent TRPV1 antagonists. The profiles of JTS-653, high potency in vivo and transient hyperthermia, seem to be associated with polymodal inhibition of TRPV1 activation.


Archive | 2005

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (vr1) activity

Yoshihisa Koga; Shinji Yata; Takashi Watanabe; Takuya Matsuo; Takayuki Yamasaki; Masahiro Sakata; Wataru Kondo; Hidekazu Ozeki; Yoshikazu Hori


Archive | 2005

Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor

Yoshihisa Koga; Shinji Yata; Takashi Watanabe; Takuya Matsuo; Takayuki Yamasaki; Masahiro Sakata; Wataru Kondo; Hidekazu Ozeki; Yoshikazu Hori


Archive | 2005

3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

Yoshihisa Koga; Shinji Yata; Takashi Watanabe; Takuya Matsuo; Masahiro Sakata; Wataru Kondo


Archive | 2006

3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity

Yoshihisa Koga; Shinji Yata; Takayuki Yamasaki; Tatsuya Matsumoto; Masahiro Sakata; Wataru Kondo; Yoshikazu Hori


Archive | 2005

3-aminobenamide compound and vanilloid receptor 1 (vr1) activity inhibitor

Shinji Yata; Yoshihisa Koga; Takashi Watanabe; Takuya Matsuo; Masahiro Sakata; Wataru Kondo


Archive | 1995

Osteoporosis remedy and triazepine compound

Takeshi Nakamura; Yoshihisa Koga; Masanori Shindo


Archive | 2009

3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS

Yoshihisa Koga; Shinji Yata; Takashi Watanabe; Takuya Matsuo; Masahiro Sakata; Wataru Kondo


Archive | 2006

3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity

Yoshihisa Koga; Shinji Yata; Takayuki Yamasaki; Tatsuya Matsumoto; Masahiro Sakata; Wataru Kondo; Yoshikazu Hori


Archive | 2005

Composé 3-aminobénamide et inhibiteur d'activité à récepteur vanilloïde 1 (vr1)

Shinji Yata; Yoshihisa Koga; Takashi Watanabe; Takuya Matsuo; Masahiro Sakata; Wataru Kondo

Collaboration


Dive into the Yoshihisa Koga's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge